Oscotec's SYK Inhibitor Program Gets Korea Drug Fund Money
This article was originally published in PharmAsia News
Oscotec is set to accelerate the development of a novel oral rheumatoid arthritis drug, helped by financial support from the state-run Korea Drug Development Fund for a US Phase I clinical trial of the South Korean venture’s spleen tyrosine kinase inhibitor.
You may also be interested in...
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
In the midst of the ongoing COVID-19 pandemic, Korea promotes its Centers For Disease Control & Prevention to a central administrative agency that will act as an infectious disease "control tower" that independently carries out investigation and research and sets infectious disease policy. A dedicated vice-minister of health and welfare has also been appointed to step up the public health and medical system.
NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.